drugset / Trial / NCT00338494

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

NCT00338494

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma. This research is being done to develop new treatments for patients with lymphoma whose cancer has returned or resisted treatment with previous chemotherapy.

Timeline

Start
2005-10
Primary completion
2010-03
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 10 mg/m2
Subject Clofarabine Other / unclassified 15 mg/m2
Subject Clofarabine Other / unclassified 20 mg/m2
Subject Clofarabine Other / unclassified 30 mg/m2
Subject Clofarabine Other / unclassified 40 mg/m2

Indications